-DOCSTART- -X- O
Sepsis -X- _ O
is -X- _ O
a -X- _ O
major -X- _ O
cause -X- _ O
of -X- _ O
mortality -X- _ O
during -X- _ O
the -X- _ O
neutropenic -X- _ O
phase -X- _ O
after -X- _ O
intensive -X- _ O
cytotoxic -X- _ O
therapies -X- _ O
for -X- _ O
malignancies. -X- _ O
Improved -X- _ B-Outcome
management -X- _ I-Outcome
of -X- _ I-Outcome
sepsis -X- _ I-Outcome
during -X- _ I-Outcome
neutropenia -X- _ I-Outcome
may -X- _ I-Outcome
reduce -X- _ I-Outcome
the -X- _ I-Outcome
mortality -X- _ I-Outcome
of -X- _ I-Outcome
cancer -X- _ I-Outcome
therapies. -X- _ I-Outcome
Clinical -X- _ O
guidelines -X- _ O
on -X- _ O
sepsis -X- _ O
treatment -X- _ O
have -X- _ O
been -X- _ O
published -X- _ O
by -X- _ O
others. -X- _ O
However -X- _ O
, -X- _ O
optimal -X- _ O
management -X- _ O
may -X- _ O
differ -X- _ O
between -X- _ O
neutropenic -X- _ B-Patient
and -X- _ I-Patient
non-neutropenic -X- _ I-Patient
patients. -X- _ I-Patient
Our -X- _ O
aim -X- _ O
is -X- _ O
to -X- _ O
give -X- _ O
evidence-based -X- _ O
recommendations -X- _ O
for -X- _ O
haematologist -X- _ O
, -X- _ O
oncologists -X- _ O
and -X- _ O
intensive -X- _ O
care -X- _ O
physicians -X- _ O
on -X- _ O
how -X- _ O
to -X- _ O
manage -X- _ O
adult -X- _ B-Patient
patients -X- _ I-Patient
with -X- _ I-Patient
neutropenia -X- _ I-Patient
and -X- _ O
sepsis -X- _ O
. -X- _ O

